Nature 1993, 362: 755–758.CrossRefPubMed Enzalutamide mw 25. Chen TT, Tao MH, Levy R: Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy

of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J Immunol 1994, 153: 4775–4787.PubMed 26. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997, 186: 1623–1631.CrossRefPubMed 27. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997, 3: 849–854.CrossRefPubMed 28. Massa S, Franconi R, Brandi R, Muller A, Mett V, Lazertinib purchase Yusibov V, Venuti A: Anti-cancer activity of plant-produced HPV16 E7 vaccine. Vaccine 2007, 25: 3018–3021.CrossRefPubMed

29. Venuti A, Massa S, Mett V, Dalla Vedova L, Paolini F, Franconi V, Yusibov V: An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine 2009, in press. 30. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA: Targeting p53 as a general tumour antigen. Proc Natl Acad Sci USA 1995, 92: 11993–11997.CrossRefPubMed 31. DeLeo AB: p53-based immunotherapy of cancer. Crit Rev Immunol 1998, 18: 29–35.PubMed 32. Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, DeLeo AB: Generation of anti-p53 Selleck PF-04929113 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999, 5: 1281–1288.PubMed 33. Gurunathan

S, Klinman DM, Seder RA: DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000, 18: 927–974.CrossRefPubMed 34. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002, 20: 621–667.CrossRefPubMed 35. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, second Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408: 740–745.CrossRefPubMed 36. Moniz M, Ling M, Hung CF, Wu TC: HPV DNA vaccines. Front Biosci 2003, 8: 55–68. Review.CrossRef 37. Massa S, Simeone P, Muller A, Benvenuto E, Venuti A, Franconi R: Antitumour activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein. Hum Gene Ther 2008, 19: 354–64.CrossRefPubMed 38. O’Malley BW Jr, Li D, McQuone SJ, Ralston R: ombination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope 2005, 115: C391–404.CrossRef 39. Ling M, Wu TC: Therapeutic human papillomavirus vaccines. In Cervical cancer: from etiology to prevention. Edited by: Rohan TE, Shah KV. Boston: Kluwer Academic Publishers; 2004:345–376.CrossRef 40.